Details of the Drug

General Information of Drug (ID: DM4PUDW)

Drug Name
L-Glutamic Acid
Synonyms
Aciglut; Glu; Glusate; Glut; Glutacid; Glutamicol; Glutamidex; Glutaminol; Glutaton; Gulutamine; Acide glutamique; Acido glutamico; Acidum glutamicum; Acidum glutaminicum; Glutamic acid polymer; Glutaminic acid; E 620; A-Aminoglutaric acid; A-Glutamic acid; Acide glutamique [INN-French]; Acido glutamico [INN-Spanish]; Acidum glutamicum [INN-Latin]; D-Glutamiensuur; Glutamic Acid [USAN:INN]; Glutamic acid (VAN); Glutaminic acid (VAN); Gulutamine (USP); L-Glutamic acid hydrochloride; L-Glutaminic acid; L-Glutaminsaeure; L-glu; L-glutamate; Alpha-Aminoglutaric acid (VAN); Alpha-L-Glutamic acid polymer; Glutamic Acid (L-glutamic acid); Glutamic acid (H-3); H-Glu-OH; L-2-Aminoglutaric acid; L-Glutamic acid (9CI); L-Glutamic acid (JAN); L-Glutamic acid, homopolymer; L-a-Aminoglutaric acid; L-alpha-Aminoglutaric acid; Poly-L-glutamate; Sodium Glutamate (L-glutamic Acid); Glutamic acid, L-, peptides; L-Glutamic acid, homopolymer (9CI); Poly(alpha-L-glutamic acid); Glutamic acid, L-(7CI,8CI); L-(+)-glutamic acid; (S)-(+)-Glutamic acid; (S)-2-Aminopentanedioic acid; (S)-Glutamic acid; 1-Aminopropane-1,3-dicarboxylic acid
Indication
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Approved [1]
Therapeutic Class
Dietary supplement
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 147.13
Logarithm of the Partition Coefficient (xlogp) -3.7
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 3
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
Metabolism
The drug is metabolized via the hepatic []
Chemical Identifiers
Formula
C5H9NO4
IUPAC Name
(2S)-2-aminopentanedioic acid
Canonical SMILES
C(CC(=O)O)[C@@H](C(=O)O)N
InChI
InChI=1S/C5H9NO4/c6-3(5(9)10)1-2-4(7)8/h3H,1-2,6H2,(H,7,8)(H,9,10)/t3-/m0/s1
InChIKey
WHUUTDBJXJRKMK-VKHMYHEASA-N
Cross-matching ID
PubChem CID
33032
ChEBI ID
CHEBI:16015
CAS Number
56-86-0
DrugBank ID
DB00142
TTD ID
D00ENY
VARIDT ID
DR00005

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
N-methyl-D-aspartate receptor (NMDAR) TT9IK2Z NOUNIPROTAC Antagonist [2]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter-like 3 (SLC22A13) DT38SZL S22AD_HUMAN Substrate [3]
Cystine/glutamate transporter (SLC7A11) DTKLMH6 XCT_HUMAN Substrate [4]
Calcium-binding mitochondrial carrier protein Aralar2 (SLC25A13) DTDSYAQ CMC2_HUMAN Substrate [5]
Sodium-independent aspartate/glutamate transporter 1 (SLC7A13) DTMWE5P S7A13_HUMAN Substrate [6]
Calcium-binding mitochondrial carrier protein Aralar1 (SLC25A12) DT85HYR CMC1_HUMAN Substrate [7]
Putative sodium-coupled neutral amino acid transporter 8 (SLC38A8) DT0UQDA S38A8_HUMAN Substrate [8]
Putative sodium-coupled neutral amino acid transporter 10 (SLC38A10) DT2LGOY S38AA_HUMAN Substrate [9]
Excitatory amino acid transporter 4 (SLC1A6) DTV2AOB EAA4_HUMAN Substrate [10]
Excitatory amino acid transporter 1 (SLC1A3) DT9U216 EAA1_HUMAN Substrate [10]
Vesicular glutamate transporter 1 (SLC17A7) DTNK0FR VGLU1_HUMAN Substrate [11]
Vesicular glutamate transporter 2 (SLC17A6) DT5LHCR VGLU2_HUMAN Substrate [11]
Mitochondrial glutamate carrier 1 (SLC25A22) DTJCWP8 GHC1_HUMAN Substrate [12]
Mitochondrial glutamate carrier 2 (SLC25A18) DT3VZJO GHC2_HUMAN Substrate [13]
Excitatory amino acid transporter 5 (SLC1A7) DTBGZ8H EAA5_HUMAN Substrate [10]
Vesicular glutamate transporter 3 (SLC17A8) DTAGDH7 VGLU3_HUMAN Substrate [11]
Excitatory amino acid transporter 2 (SLC1A2) DT0VAI5 EAA2_HUMAN Substrate [14]
Excitatory amino acid transporter 3 (SLC1A1) DTJIRMD EAA3_HUMAN Substrate [15]
Organic anion transporter 4 (SLC22A11) DT06JWZ S22AB_HUMAN Substrate [16]
Organic anion transporting polypeptide 2B1 (SLCO2B1) DTPFTEQ SO2B1_HUMAN Substrate [17]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Acetylcholinesterase (ACHE) OT2H8HG6 ACES_HUMAN Gene/Protein Processing [18]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Gene/Protein Processing [18]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Gene/Protein Processing [18]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [18]
Transient receptor potential cation channel subfamily M member 4 (TRPM4) OT354X8E TRPM4_HUMAN Gene/Protein Processing [19]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from L-Glutamic Acid (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Lisdexamfetamine DM6W8V5 Moderate Decreased absorption of L-glutamic acid due to altered gastric pH caused by Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [20]
Amphetamine DMSZQAK Moderate Decreased absorption of L-glutamic acid due to altered gastric pH caused by Amphetamine. Attention deficit hyperactivity disorder [6A05] [20]
Dextroamphetamine DMMIHVP Moderate Decreased absorption of L-glutamic acid due to altered gastric pH caused by Dextroamphetamine. Narcolepsy [7A20] [20]
Benzphetamine DMIJATC Moderate Decreased absorption of L-glutamic acid due to altered gastric pH caused by Benzphetamine. Obesity [5B80-5B81] [20]
Methamphetamine DMPM4SK Moderate Decreased absorption of L-glutamic acid due to altered gastric pH caused by Methamphetamine. Pain [MG30-MG3Z] [21]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1369).
2 Altered expression of genes involved in GABAergic transmission and neuromodulation of granule cell activity in the cerebellum of schizophrenia pati... Am J Psychiatry. 2008 Dec;165(12):1594-603.
3 SLC22A13 catalyses unidirectional efflux of aspartate and glutamate at the basolateral membrane of type A intercalated cells in the renal collecting duct. Biochem J. 2014 Jan 15;457(2):243-51.
4 The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate. J Biol Chem. 2017 Aug 25;292(34):14240-14249.
5 Epigenetic upregulation and functional role of the mitochondrial aspartate/glutamate carrier isoform 1 in hepatocellular carcinoma. Biochim Biophys Acta Mol Basis Dis. 2019 Jan;1865(1):38-47.
6 Novel cystine transporter in renal proximal tubule identified as a missing partner of cystinuria-related plasma membrane protein rBAT/SLC3A1. Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):775-80.
7 Mitochondrial Aspartate/Glutamate Carrier SLC25A12 and Autism Spectrum Disorder: a Meta-Analysis. Mol Neurobiol. 2016 Apr;53(3):1579-1588.
8 Structural modeling of a novel SLC38A8 mutation that causes foveal hypoplasia. Mol Genet Genomic Med. 2017 Feb 26;5(3):202-209.
9 The neuronal and astrocytic protein SLC38A10 transports glutamine, glutamate, and aspartate, suggesting a role in neurotransmission. FEBS Open Bio. 2017 Apr 26;7(6):730-746.
10 The SLC1 high-affinity glutamate and neutral amino acid transporter family. Mol Aspects Med. 2013 Apr-Jun;34(2-3):108-20.
11 Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res Brain Res Rev. 2004 Jul;45(3):250-65.
12 Impaired mitochondrial glutamate transport in autosomal recessive neonatal myoclonic epilepsy. Am J Hum Genet. 2005 Feb;76(2):334-9.
13 The ABCs of membrane transporters in health and disease (SLC series): Introduction. Molecular Aspects of Medicine, 2013, 34(2-3):95-107. (GeneName=SLC25A18)
14 EAAT2 (GLT-1; slc1a2) glutamate transporters reconstituted in liposomes argues against heteroexchange being substantially faster than net uptake. J Neurosci. 2014 Oct 1;34(40):13472-85.
15 Loss-of-function mutations in the glutamate transporter SLC1A1 cause human dicarboxylic aminoaciduria. J Clin Invest. 2011 Jan;121(1):446-53.
16 The role of the intracellular glutamate gradient in driving organic anion transporter function.
17 The Transporter Classification Database (TCDB): recent advances. Nucleic Acids Res. 2016 Jan 4;44(D1):D372-9. (ID: 2.A.60.1.20)
18 Dihydroactinidiolide regulates Nrf2/HO-1 expression and inhibits caspase-3/Bax pathway to protect SH-SY5Y human neuroblastoma cells from oxidative stress induced neuronal apoptosis. Neurotoxicology. 2021 May;84:53-63. doi: 10.1016/j.neuro.2021.02.006. Epub 2021 Feb 20.
19 Depletion of 14-3-3 reduces the surface expression of Transient Receptor Potential Melastatin 4b (TRPM4b) channels and attenuates TRPM4b-mediated glutamate-induced neuronal cell death. Mol Brain. 2014 Jul 22;7:52. doi: 10.1186/s13041-014-0052-3.
20 Product Information. Dexedrine (dextroamphetamine) SmithKline Beecham, Philadelphia, PA.
21 Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68. [PMID: 7768079]